Abstract
Background
Cystoid macular edema (CME) is one of the common complications of retinitis pigmentosa (RP), and is responsible for patient complications such as blurred and reduced visual acuity and for subsequent atrophic changes in the fovea. The objective of this work was to evaluate the clinical efficacy of a topical dorzolamide (a carbonic anhydrase inhibitor) in CME associated with RP.
Methods
Sixteen eyes of nine patients with CME secondary to typical forms of RP were included in the study. Baseline visual acuity, visual field, and optical coherence tomography (OCT) measurements were obtained for all patients. All patients used 1% dorzolamide three times daily in each eye. Patients underwent follow-up exams at 1, 3, and 6 months after treatment. The response to treatment was monitored by visual acuity and visual field measurement testing using the Humphrey Field Analyzer (HFA: the central 10-2 Program); in addition, foveal thickness was measured by OCT. Evaluation of macular sensitivity calculated by HFA as the average of 12 central points.
Results
Thirteen (81.3%) of 16 eyes showed a clear decrease in retinal thickness after treatment. Evaluation of macular sensitivity, calculated by HFA as the average of 12 central points (with the exception of foveal point data, showed an improvement of more than 1.0 dB in nine (56.3%) of 16 eyes. Moreover, both the mean deviation value and macular sensitivity were significantly improved. No severe side-effects were seen in any of the patients examined.
Conclusions
The results demonstrated that a topical dorzolamide is effective for the treatment of CME in patients with RP, and that the positive treatment effects last for up to 6 months.
Similar content being viewed by others
References
Pruett RC (1983) Retinitis pigmentosa: clinical observations and correlations. Trans Am Ophthalmol Soc 81:693–735
Berson EL (1993) Retinitis pigmentosa. The Friedenwald lecture. Invest Ophthalmol Vis Sci 34:1659–1676
Grover S, Fishman GA, Anderson RJ, Alexander KR, Derlacki DJ (1997) Rate of visual field loss in retinitis pigmentosa. Ophthalmology 104:460–465
Fishman GA, Maggiano JM, Fishman M (1977) Foveal lesions seen in retinitis pigmentosa. Arch Ophthalmol 95:1993–1996
Hirakawa H, Iijima H, Gohdo T, Tsukahara S (1999) Optical coherence tomography of cystoid macular edema associated with retinitis pigmentosa. Am J Ophthalmol 128:185–191
Hajali M, Fishman GA, Anderson RJ (2008) The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography. Br J Ophthalmol 92:1065–1068
Sandberg MA, Brockhurst RJ, Gaudio AR, Berson EL (2005) The association between visual acuity and central retinal thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci 46:3349–3354
Sandberg MA, Brockhurst RJ, Gaudio AR, Berson EL (2008) Visual acuity is related to parafoveal retinal thickness in patients with retinitis pigmentosa and macular cysts. Invest Ophthalmol Vis Sci 49:4568–7452
Cox SN, Hay E, Bird AC (1988) Treatment of chronic macular edema with acetazolamide. Arch Ophthalmol 106:1190–1195
Fishman GA, Gilbert LD, Fiscella RG, Kimura AE, Jampol LM (1989) Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa. Arch Ophthalmol 107:1445–1452
Ozdemir H, Karacorlu M, Karacorlu S (2005) Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand 83:248–251
García-Arumí J, Martinez V, Sararols L, Corcostegui B (2003) Vitreoretinal surgery for cystoid macular edema associated with retinitis pigmentosa. Ophthalmology 110:1164–1169
Grover S, Apushkin MA, Fishman GA (2006) Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 141:850–858
Fishman GA, Apushkin MA (2007) Continued use of dorzolamide for the treatment of cystoid macular oedema in patients with retinitis pigmentosa. Br J Ophthalmol 91:743–745
Ito Y, Terasaki H, Takahashi A, Yamakoshi T, Kondo M, Nakamura M (2005) Dissociated optic nerve fiber layer appearance after internal limiting membrane peeling for idiopathic macular holes. Ophthalmology 112:1415–1420
Heckenlively JR, Jordan BL, Aptsiauri N (1999) Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 127:565–573
Vinores SA, Küchle M, Derevjanik NL, Henderer JD, Mahlow J, Green WR, Campochiaro PA (1995) Blood–retinal barrier breakdown in retinitis pigmentosa: light and electron microscopic immunolocalization. Histol Histopathol 10:913–923
Wolfensberger TJ (1999) The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol 97:387–397
Moldow B, Sander B, Larsen M, Engler C, Li B, Rosenberg T, Lund-Andersen H (1998) The effect of acetazolamide on passive and active transport of fluorescein across the blood–retina barrier in retinitis pigmentosa complicated by macular oedema. Graefes Arch Clin Exp Ophthalmol 236:881–889
Moldow B, Sander B, Larsen M, Lund-Andersen H (1999) Effects of acetazolamide on passive and active transport of fluorescein across the normal BRB. Invest Ophthalmol Vis Sci 40:1770–1775
Apushkin MA, Fishman GA, Grover S, Janowicz MJ (2007) Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa. Retina 27:1112–1128
Cheeks L, Green K (1986) Distribution of a steroid antagonist in the eye following topical administration. Curr Eye Res 5:705–709
Conroy CW (1997) Sulfonamides do not reach the retina in therapeutic amounts after topical application to the cornea. J Ocul Pharmacol Ther 13:465–472
Mizuno K, Koide T, Saito N, Fujii M, Nagahara M, Tomidokoro A, Tamaki Y, Araie M (2002) Topical nipradilol: effects on optic nerve head circulation in humans and periocular distribution in monkeys. Invest Ophthalmol Vis Sci 43:3243–3250
Chung H, Hwang JU, Kim JG, Yoon YH (2006) Optical coherence tomography in the diagnosis and monitoring of cystoid macular edema in patients with retinitis pigmentosa. Retina 26:922–927
Acknowledgements
KN International provided language assistance. This work was supported in part by a Grant-in-Aid (to YI) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (#20791259). None of the authors has any financial interests to disclose.
Competing interests
None
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported in part by a Grant-in-Aid (to YI) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (#20791259).
Clinical Trial Registration: UMIN000005852 (http://www.umin.ac.jp)
Rights and permissions
About this article
Cite this article
Ikeda, Y., Hisatomi, T., Yoshida, N. et al. The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 250, 809–814 (2012). https://doi.org/10.1007/s00417-011-1904-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-011-1904-5